<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139639">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02011282</url>
  </required_header>
  <id_info>
    <org_study_id>CIM-TRIAL</org_study_id>
    <nct_id>NCT02011282</nct_id>
  </id_info>
  <brief_title>ELECTRO-NEURO-MUSCULAR STIMULATION IN ICU</brief_title>
  <official_title>ELECTRO-NEURO-MUSCULAR STIMULATION IN HOSPITALIZED INTENSIVE CARE PATIENTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Thessaly</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Thessaly</source>
  <oversight_info>
    <authority>Greece: Ministry of Health and Welfare</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will examine whether the application of electro-neuro-muscular stimulation (ENMS) in
      critical care patients, can decrease the impact or severity of the critical illness myopathy
      (CIM) or neuropathy. We will also assess whether electro-neuro-muscular stimulation affect
      the incidence density rate of nosocomial pneumonia in the ICU.

      Patients will be divided into two groups, Group A and Group B chosen at random. In Group A
      conventional physiotherapy will be applied while in Group B, ENMS will also be applied
      additional to physiotherapy, in the quadriceps muscles. The total time of applying ENMS will
      be 1 hour, it will be applied before the start of the physiotherapy per day of
      hospitalization and for 10 days in each patient.

      The definition of CIM will be based on pathology muscular biopsy (quadriceps). Patients will
      undergo biopsy on the 1st and 11th day after entering the study. The technique of Gomori
      Trichrome will be used to determine the existence or absence of myopathy. In addition the
      ATPase technique will be applied at different prices of PH (PH: 9,4, PH: 4,6 and PH : 4.3),
      thus achieving a separation of myopathy and neuropathy.

      The primary outcome of the study will be the incidence of myopathy in both groups, at day
      12th. Considering that the incidence of myopathy in critically ill patients is 80% reducing
      this rate by 50% in the intervention group using statistical power equal to 0.80 up to a
      level of p &lt;0.05, 12 number of patients will be required in each group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>incidence of myopathy</measure>
    <time_frame>12 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Presence of myopathy in critical care patients; myopathy will be assessed with biopsy of quadriceps at  day 12 after entering the study (17 day of ICU hospitalization)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NEUROPATHY</measure>
    <time_frame>12 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>presence of peripheral neuropathy after 12 days of hospitalization in the ICU</description>
  </secondary_outcome>
  <other_outcome>
    <measure>ventilator associated pneumonia</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>presence of ventilator associated pneumonia during 28 days of stay in the ICU</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>PREVENTION OF MYOPATHY AND NEUROPATHY IN CRITICAL CARE PATIENTS</condition>
  <arm_group>
    <arm_group_label>ELECTRO-NEURO-MUSCULAR STIMULATION</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive daily sessions of electrostimulation with a commercially available device (En-Stimulation 4, Netherlands) in the quadriceps muscle for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this arm will receive the usual standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patients will receive daily sessions of electro-neuro-stimulation in the quadriceps muscle for 10 days</intervention_name>
    <arm_group_label>ELECTRO-NEURO-MUSCULAR STIMULATION</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients aged&gt;18 years old and &lt;85 years old, hospitalized in the ICU for at least 96
        hours

        Exclusion Criteria:

        pregnancy, autoimmune disease, pre-existing known neuromuscular diseases, presence of bone
        fractures on the lower extremities, use of corticoids
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>EPAMINONDAS ZAKYNTHINOS, PROF</last_name>
    <role>Study Director</role>
    <affiliation>University of Thessaly</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>EPAMINONDAS ZAKYNTHINOS, PROF</last_name>
    <phone>00302413501280</phone>
    <email>ezakynth@yahoo.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Icu University Hospital Larissa</name>
      <address>
        <city>Larissa</city>
        <state>Thessaly</state>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>EPAMINONDAS ZAKYNTHINOS, PROF</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>EVAGGELIA KOUTSIOUMPA, PHYSIOTHER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 9, 2013</lastchanged_date>
  <firstreceived_date>December 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Thessaly</investigator_affiliation>
    <investigator_full_name>DEMOSTHENES MAKRIS</investigator_full_name>
    <investigator_title>ASS. Professor in Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>ICU,MYOPATHY, NEUROPATHY, PNEUMONIA</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
